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ORIGINAL ARTICLE
Chitosan nanoparticles for daptomycin delivery in ocular treatment
of bacterial endophthalmitis
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1CBQF – Centre for Biotechnology and Fine Chemistry – State Associated Laboratory, College of Biotechnology, Catholic University of Portugal/
Porto, Porto, Portugal and 2Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Porto, Portugal
Abstract
Context: Chitosan nanoparticles were prepared to encapsulate daptomycin and proposed as a
delivery system of this antibiotic to the eye for the treatment of bacterial endophthalmitis.
Objective: The aim of this study was to develop daptomycin-loaded nanoparticles to apply
directly to the eye, as a possible non-invasive and less painful alternative for the treatment of
endophthalmitis, increasing the effectiveness of treatment and reducing toxicity associated
with systemic administration.
Materials and methods: Nanoparticles were obtained by ionotropic gelation between
chitosan and sodium tripolyphosphate (TPP). Physicochemical and morphological character-
istics of nanoparticles were evaluated, as well as determination of antimicrobial efficiency
of encapsulated daptomycin and stability of the nanoparticles in the presence of lysozyme and
mucin.
Results: Loaded nanoparticles presented mean particle sizes around 200 nm, low polydispersity
index, and positive zeta potential. Morphological examination by scanning electron microscopy
(SEM) confirmed their small size and round-shaped structure. Encapsulation efficiency ranged
from 80 to 97%. Total in vitro release of daptomycin was obtained within 4 h. Determination
of minimum inhibitory concentrations (MICs) showed that bacteria were still susceptible to
daptomycin encapsulated into the nanoparticles. Incubation with lysozyme did not significantly
affect the integrity of the nanoparticles, although mucin positively affected their mucoadhesive
properties.
Discussion and conclusion: The obtained nanoparticles have suitable characteristics for ocular
applications, arising as a promising solution for the topical administration of daptomycin to
the eye.
Keywords
Antibacterial activity, chitosan, daptomycin,
nanoparticles, ocular infection
History
Received 9 September 2013
Revised 13 October 2013
Accepted 18 October 2013
Introduction
The human eye, due to its position, is constantly exposed
to the surrounding environment and to a wide range of
pathogenic microorganisms. Serious eye infections can affect
the ocular globe causing sight-threatening conditions, such as
endophthalmitis. Bacterial endophthalmitis is an ocular
inflammation resulting from the infection of the posterior
segment of the eye by pathogenic microorganisms (Callegan
et al., 2007). Endophthalmitis frequently culminates in severe
visual disabilities causing irreversible damage to the photo-
receptor cells of the retina, and it can result in partial or
complete vision loss (Callegan et al., 2002).
Gram-positive microorganisms are the most common
bacterial pathogens causing endophthalmitis (Romero et al.,
1999). Endogenous endophthalmitis is usually caused by
Staphylococcus aureus and Streptococcus species (Bispo et al.,
2008). Bacteria causing acute post-operative endophthalmitis
have usually colonized ocular surface structures and include
mainly coagulase-negative staphylococci, S. aureus,
Streptococcus viridans, and other Gram-positive cocci and
Gram-negative bacilli (Kresloff et al., 1998; Bispo et al., 2008).
Enterococci are also relevant in post-operative cases, both for
prevalence and severity of disease (Callegan et al., 2002).
Daptomycin is a natural lipopeptide antibiotic active
against most Gram-positive microorganisms implicated in
bacterial endophthalmitis (Jeu & Fung, 2004; Robbel &
Marahiel, 2010). It is active against some antibiotic resist-
ant bacteria, including methicillin-resistant S. aureus
(MRSA), methicillin-resistant Staphylococcus epidermidis,
penicillin-resistant Streptococcus pneumoniae, and vanco-
mycin-resistant enterococci (Thorne & Alder, 2002).
Daptomycin has been approved for the nontopical treat-
ment of skin structure infections caused by Gram-positive
bacteria, as well as for the treatment of bacteremia and
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right-sided endocarditis caused by S. aureus strains (Enoch
et al., 2007; Robbel & Marahiel, 2010). It is available for
intravenous route only, which means invasiveness and high
hospital costs. Nonetheless, daptomycin may offer a novel
antibacterial tool for the treatment of endophthalmitis, in
particular if caused by MRSA.
Local drugs applied to the eye represent a non-invasive,
safe, and less painful solution. However, treatment of
bacterial infections in the eye is particularly difficult due to
innate protective barriers in the precorneal area of the eye.
Both corneal and conjunctival epithelia have tight junctions
that limit the entrance of substances into the eye, including
beneficial molecules such as antibiotics (Kinoshita et al.,
2001; Nanjawade et al., 2007). Also, the mucus layer in
the eye blocks the entrance of not only debris particles
but also medicines, which are then removed through
the lachrymal system (Corfield et al., 1997; de Campos
et al., 2004).
Due to these limitations, drug delivery systems for topical
ocular administration are interesting alternatives, especially
due to the non-invasive way of releasing drugs in a controlled
fashion directly to the eye (Diebold & Calonge, 2010).
Among the possible strategies, the use of mucoadhesive
polymeric carriers able to interact intimately with extraocular
structures has been considered very promising (Ding, 1998;
Motwani et al., 2008; Zarbin et al., 2010). In particular,
chitosan has some favorable properties for controlled drug
delivery to the eye. It is biocompatible, biodegradable,
mucoadhesive, and non-toxic (de Campos et al., 2004;
Severino et al., 2007). Mucoadhesive properties of chitosan
contribute to enhance the residence time of the delivery
system in the precorneal area, thus increasing drug penetra-
tion across intraocular structures and decreasing the fre-
quency of administration. Biocompatibility of chitosan with
ocular structures increases the contact time of drugs on the
cornea, improving topical absorption and avoiding invasive
treatments (Severino et al., 2007). Also, chitosan has pene-
tration-enhancing properties, which results in reorganization
and opening of tight junctions between epithelial cells,
especially important in the transport of hydrophilic com-
pounds such as therapeutic peptides (Mourya & Inamdar,
2008; de la Fuente et al., 2010; Subramanian et al., 2011).
Until now, no study has demonstrated the potential of chitosan
nanosystems for the protection of antimicrobial lipopeptides
for efficient ocular administration.
Materials and methods
Materials
Daptomycin (degree of purity 94.9%) was a gift from Novartis
Pharma AG (Basel, Switzerland). Low molecular weight
chitosan with a degree of deacetylation of 85% and sodium
tripolyphosphate (TPP) with a technical grade of 85% were
obtained from Sigma-Aldrich (St. Louis, MO). Acetic acid
at 100% was purchased from Pronalab (Lisbon, Portugal).
Sodium hydroxide (NaOH) and hydrochloric acid (HCl)
were from Merck (Darmstadt, Germany). Acetonitrile,
trifluoroacetic acid, and triethylamine were of analytical
grade and purchased from Sigma-Aldrich (USA), as well as
lysozyme and mucin. Ultra-pure water was obtained in our
laboratory using a Millipore water purification equipment
(Billerica, MA).
Preparation of chitosan nanoparticles
Determination of the isoelectric point of daptomycin
For determination of the isoelectric point of daptomycin,
1 mg/mL of daptomycin solutions were prepared in ultra-pure
water and adjusted to different pH values (pH¼ 2.25, 3.20,
4.30, 4.40, 5.33, and 5.47) with 1 M NaOH or 1 M HCl.
The electric charge of daptomycin molecules was then
determined by laser Doppler anemometry using ZetaPALS –
Zeta Potential and Particle Size Analyzer (Brookhaven, NY).
Preparation of unloaded nanoparticles
In order to determine the optimal experimental conditions
for the formation of nanoparticles, various concentrations
of chitosan and TPP were tested. Chitosan was dissolved in
acetic acid solutions in order to achieve final chitosan
concentrations of 0.05, 0.5, 1, 2, 3, and 5 mg/mL. In all
cases, concentration of acetic acid was 1.75 times higher than
that of chitosan, as suggested by Calvo et al. (1997a). The pH
of chitosan solutions was adjusted to 5.4–5.5 with 1 M NaOH.
TPP solutions were prepared in ultra-pure water at final
concentrations of 0.05, 0.1, 0.2, 0.5, 1, and 2 mg/mL.
To determine the influence of chitosan concentration on
nanoparticle formation, 2 mL of a TPP solution (1 mg/mL)
was added dropwise to 5 mL of the different chitosan
solutions previously prepared, under magnetic stirring
(1000 rpm) for 90 seconds, at room temperature. The same
procedure was used to determine the influence of TPP
concentration. Thus, 2 mL of the prepared TPP solutions at
different concentrations was added to 5 mL of a chitosan
solution (2 mg/mL), at the same temperature and stirring
conditions stated above. The experiments were performed in
triplicate.
Preparation of daptomycin-loaded nanoparticles
Daptomycin-loaded nanoparticles were formed spontaneously
upon dropwise addition of 2 mL of TPP solution (1 mg/mL) to
5 mL of chitosan solution (2 mg/mL), under magnetic stirring
(1000 rpm) for 90 seconds, at room temperature. Daptomycin
was incorporated into nanoparticles by diluting daptomycin
stock solution in pH-adjusted chitosan solution, in order to
achieve final daptomycin:chitosan mass ratios of 0.05:1,
0.1:1, 0.15:1, 0.2:1, and 0.3:1. An alternative methodology
was performed in which daptomycin was added to the TPP
solution, instead of being incorporated into the chitosan
solution. The experiments were performed in triplicate.
Nanoparticle suspensions were centrifuged at 20 000 g
for 20 min (Sigma-Laboratory centrifuges, Osterode am Harz,
Germany). Supernatants were collected and stored at 20 C
for daptomycin assay by reverse-phase high-performance
liquid chromatography (RP-HPLC), while nanoparticles were
stored in the centrifugal tube at 4 C for further analysis.
Physicochemical and morphological characterization
Particle size and polydispersity of freshly prepared
unloaded and loaded nanoparticles were determined by
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photon correlation spectroscopy using ZetaPALS (USA).
Nanoparticle suspensions were analyzed at 25 C with a
detection angle of 90. Zeta potential was determined by laser
Doppler anemometry, at 25 C, using the same equipment.
Scanning electron microscopy (SEM) was used to observe
the morphology of the nanoparticles. Unloaded and dapto-
mycin-loaded nanoparticles were dried at room temperature
and placed on metal stubs with adhesive tape, sputter coated
with gold (SC7620 Sputter Coater, Quorum Technologies,
UK), and then observed under a scanning electron microscope
(JSM-5600LV, JEOL, Japan) operating in high vacuum mode
at an accelerating voltage of 20 kV.
Determination of encapsulation efficiency
Encapsulation efficiency of daptomycin-loaded nanoparticles
was calculated as the difference between the total amount of
daptomycin used to prepare the nanoparticles and the amount
of daptomycin present in the supernatant after centrifugation
of nanoparticle suspensions, as shown in Equation (1):
Encapsulation efficiency ð%Þ
¼
Total amount of daptomycin
Free amount of daptomycin
 
Total amount of daptomycin
ð1Þ
Daptomycin content in the supernatant was determined by
RP-HPLC using a method adapted from Martens-Lobenhoffer
et al. (2008). The chromatographic equipment consisted of an
Alliance HPLC system (Waters Corporation, Massachusetts,
USA) and the analytical column was a ZORBAX Eclipse
XDB-C8 4.6 150 mm 5 mm particle size (Agilent
Technologies, Santa Clara, CA). Briefly, the mobile phase
for the chromatographic separation of daptomycin consisted
of pure acetonitrile and a buffer solution prepared with
20 mM trifluoroacetic acid and 15 mM triethylamine in ultra-
pure water. For the chromatographic separation, a gradient
was applied starting at 30% acetonitrile and rising to 40%
acetonitrile in 5 min, then constant for 3 min, and finally
decreasing to 30% acetonitrile for 3 min. The applied flow
rate was 1 mL/min, the column temperature was set to 30 C,
and the injection volume was 50 mL. For quantification of
daptomycin, peak areas at 224 nm were determined.
In vitro release profile of daptomycin
For daptomycin in vitro release studies, loaded nanoparticles
were suspended in 10 mL of a phosphate-buffered saline
(PBS) solution, pH 7.4, and placed in a water bath at 37 C
with gentle agitation. At 30 min, 1, 2, 3, 4, 5, and 24 h,
the suspension was centrifuged at 20 000 g for 5 min
(Sigma-Laboratory centrifuges, Germany), and 5 mL were
collected from the tube for RP-HPLC analysis. At each time,
the tube was replenished with 5 mL of PBS solution.
Determination of minimum inhibitory concentration
Determination of minimum inhibitory concentration (MIC)
was performed according to Clinical and Laboratory
Standards Institute (CLSI, 2005a,b) guidelines for the broth
microdilution method, described in M7-A6 (2005a) and
M100-S15 (2005b) documents.
Assays were performed in 96-well microplates (Nunc,
Roskilde, Denmark) in order to test free daptomycin,
unloaded nanoparticles, and daptomycin-loaded nanoparti-
cles. Tested daptomycin concentrations ranged from
0.06 to 16 mg/L. The Muller–Hinton (MH) broth (Biokar
Diagnostics, Beauvauis, France) was adjusted to a final
calcium concentration of 50 mg/L and used to prepare the
inocula and dilute the samples. Inocula were prepared by
suspending bacteria colonies (grown in Nutrient agar media
for 24 h) in calcium adjusted MH broth to a turbidity
equivalent to that of a 0.5 McFarland standard (corresponds
to 1 108 CFU/mL). The inocula were then diluted (1:100)
and the final test concentration of bacteria in the wells was
5 105 CFU/mL.
Assays were performed in duplicate against the following
organisms, obtained from a culture collection of our labora-
tory: MRSA ATCC 43300, methicillin-susceptible S. aureus
(MSSA) ATCC 25923, S. epidermidis ATCC 14990,
Staphylococcus lugdunensis ATCC 43809, Staphylococcus
haemolyticus ATCC 29970, Staphylococcus hominis
ATCC 27844, Staphylococcus warneri ATCC 27836, and
Enterococcus faecalis ATCC 29212. The MIC was deter-
mined by observing the lowest concentration that inhibited
bacterial growth.
Stability of nanoparticles in the presence of
lysozyme and mucin
Particle size, polydispersity, and zeta potential of daptomycin-
loaded nanoparticles were determined using ZetaPALS
(USA), before and after incubation of nanoparticles in
lysozyme (1 mg/mL, pH¼ 7.4) and mucin (0.4 mg/mL,
pH¼ 7.4) aqueous solutions (incubation conditions: 37 C,
under moderate stirring, for 2 h). The conditions applied in
this experiment were adapted from de Campos et al. (2004).
Loaded nanoparticles before incubation were used as controls.
Statistical analysis
Statistical analysis was performed using one-way analysis of
variance (ANOVA) with Scheffé post hoc test for comparison
of groups with normal distribution, and the Mann–Whitney
test for groups with non-normal distribution. Analysis was
performed using IBM SPSS Statistics v 19.0.0 (Chicago, IL).
Differences were considered to be significant at a level of
p50.05.
Results and discussion
Preparation and characterization of unloaded
nanoparticles
In this work we describe the preparation and characterization
of a chitosan nanoparticulate system able to incorporate
daptomycin, with appropriate mucoadhesiveness and anti-
microbial characteristics for the treatment of ocular infec-
tions. Chitosan nanoparticles were produced by ionotropric
gelation, a method based on the spontaneous formation of
complexes between chitosan and TPP, under mild conditions.
This method has enabled the formation of nanoparticles
upon mixing of chitosan and TPP solutions, through the
establishment of inter- and intramolecular bonds between
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the phosphate groups of TPP and the amino groups of
chitosan (de la Fuente et al., 2010). Usually, this method
allows the formation of nanoparticles with small diameters
(200-500 nm) and a spherical shape (Reis et al., 2006).
For the development of these nanoparticles, we first
determined the conditions necessary to the production by
testing different chitosan and TPP concentrations (Table 1).
At first, chitosan concentration was set at 2 mg/mL while TPP
solutions at different concentrations (0.05, 0.1, 0.2, 0.5, 1, and
2 mg/mL) were added dropwise to the chitosan solution.
Secondly, the same protocol was repeated but this time
TPP concentration was fixed at 1 mg/mL and added to
chitosan solutions at different concentrations (0.05, 0.5, 1, 3,
and 5 mg/mL).
Results of this experiment are presented in Table 1,
in which it can be observed that nanoparticles are formed
only when using a limited range of chitosan and TPP
concentrations. In fact, it was possible to identify two distinct
situations when mixing chitosan and TPP. For TPP concen-
trations ranging from 0.05 to 1 mg/mL, an opalescent
suspension was formed, which should correspond to a
suspension of very small particles, as suggested by Calvo
et al. (1997a). The same occurred for chitosan concentrations
of 0.05, 3, and 5 mg/mL. However, a TPP concentration
of 2 mg/mL led to the formation of aggregates that would
rapidly precipitate, as well as for chitosan concentrations
of 0.5 mg/mL and 1 mg/mL, meaning that at these concen-
trations it is not possible to obtain nanoparticles.
Considering these results, the obtained opalescent suspen-
sions were subjected to further studies and analyzed for
determination of particle size, polydispersity, and zeta
potential by photon correlation spectroscopy and laser
Doppler anemometry, respectively.
It was observed that smaller particles were produced
with increasing TPP concentrations up to 1 mg/mL. Chitosan
concentration also seems to have some influence on particle
size, as it seems to vary according to the concentration of the
chitosan solutions used to prepare the nanoparticles. However,
no statistical differences were observed among the formula-
tions tested, and thus this variation in size is not considered
significant (p40.05).
The obtained nanoparticles showed low polydispersity
values ranging from 0.171 to 0.244 (p40.05), which suggests
the presence of monodispersed particles with a narrow size
distribution (Bihari et al., 2008; Mehravar et al., 2009).
Zeta potential of the nanoparticles was also determined, since
it represents the stability of the particulate system in the sense
that the greater the absolute value of zeta potential, the greater
the surface charge of the particles. Thus, as the absolute
value of zeta potential increases, the electrostatic repulsion
interactions between the particles will be greater, the stability
of the particles will increase, and size distribution will be
more homogeneous. Zeta potential values obtained in this
study were all positive and relatively high, suggesting
good physicochemical stability of the colloidal suspensions.
Moreover, positive nanoparticles may interact with negative
surface cells like ocular cells in a stronger and longer way,
being an additional advantage of these nanoparticles. The
only exception was for the formulation with chitosan:TPP
mass ratio of 1:8, as expected from the excess TPP mass ratio
and the predominance of TPP negative charges. No statistical
differences were observed for the tested formulations con-
cerning the variations in chitosan and TPP concentrations
(p40.05).
From this experiment it can be concluded that nanoparticle
formation is only possible for some chitosan and TPP
concentrations, with the minimum nanoparticle size obtained
for the formulations prepared with chitosan concentration
of 2 mg/mL and TPP concentration of 1 mg/mL (Table 1).
Further experiments were conducted using these concentra-
tions, since they led to the production of nanoparticles with
the smallest size. Regarding zeta potential, these nanoparti-
cles were relatively stable and their positive charges are
favorable for interactions with the negatively charged residues
in mucus and cell membranes of ocular tissues.
Preparation and characterization of
daptomycin-loaded nanoparticles
To prepare daptomycin-loaded chitosan nanoparticles, the pH
of the chitosan solution was adjusted to 5.4–5.5, in order to
assure that daptomycin molecules had a negative electric
charge when daptomycin was added to chitosan solution.
This way, daptomycin molecules would interact and bond
with positively charged chitosan. In order to establish this
pH value, daptomycin solutions were prepared at different
pH values and zeta potential for these solutions was obtained.
Zeta potential corresponds to the electric charge of the






mass ratio Particle size (nm) Polydispersity Zeta potential (mV)
2 0.05 1:0.01 508.95 167.09 0.214 0.211 þ23.82 4.84
2 0.1 1:0.02 396.15 120.99 0.244 0.155 þ30.86 8.98
2 0.2 1:0.04 371.60 188.23 0.171 0.052 þ27.42 15.46
2 0.5 1:0.1 251.60 64.11 0.209 0.034 þ41.82 14.90
2 1 1:0.2 214.73 20.10 0.172 0.022 þ21.79 8.17
2 2 1:0.4 Aggregates Aggregates Aggregates
0.05 1 1:8 1568.60 1181.15 0.197 0.100 2.10 7.45
0.5 1 1:0.8 Aggregates Aggregates Aggregates
1 1 1:0.4 Aggregates Aggregates Aggregates
3 1 1:0.13 279.53 57.80 0.209 0.082 þ33.82 1.30
5 1 1:0.08 351.60 122.61 0.133 0.039 þ32.07 1.27
Concentrations of chitosan and TPP are initial concentrations, previous to nanoparticle formation.
TPP: sodium tripolyphosphate. Data shown are the mean standard deviation (n¼ 3).
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molecules and thus the isoelectric point of daptomycin was
found to be between 4.3 and 4.4.
It is known that peptides are generally better encapsulated
into chitosan nanoparticles in a medium with a pH greater
than the isoelectric point of the peptide, due to attractive
electrostatic interactions between the negatively charged
peptide molecules and the positively charged chitosan mol-
ecules (Gan & Wang, 2007). Thus, to prepare daptomycin-
loaded nanoparticles, chitosan solution had to be adjusted to
a pH value above 4.3–4.4 in order to assure that daptomycin
molecules were negatively charged. Moreover, the pH of
chitosan solution should be below 6.5, since above this value
chitosan precipitates (Nagpal et al., 2010). For this reason, to
prepare loaded nanoparticles, chitosan solution was adjusted
to pH 5.4–5.5. The same pH value was used to prepare
unloaded nanoparticles.
The incorporation of daptomycin into chitosan nanoparti-
cles was obtained by diluting a daptomycin solution either in
chitosan or TPP solution, in order to achieve final daptomy-
cin:chitosan mass ratios of 0.05:1, 0.1:1, 0.15:1, 0.2:1, and
0.3:1. Results present in Table 2 show that mean particle
size for these formulations ranged from 141.63 32.69 nm
to 204.20 19.93 nm, which seems adequate for ocular
delivery. Particle size of loaded nanoparticles seems to
generally decrease as daptomycin:chitosan mass ratio
increases. However, no statistical differences were found
among the formulations tested (p40.05). Also, no significant
differences were detected when daptomycin was added either
to chitosan or TPP solution, and when comparing loaded and
unloaded (2 mg/mL chitosan and 1 mg/mL TPP solutions)
nanoparticles (p40.05). For the morphological examination
of the nanoparticles, daptomycin-loaded nanoparticle suspen-
sions were centrifuged and dried at room temperature. These
samples were observed by scanning electron microscopy
(SEM) that revealed the presence of small round-shaped
particles with a solid structure (Figure 1). Although SEM
images showed the presence of particles, it was not possible
to confirm their actual size or surface morphology since
the equipment used in this study did not allow higher
magnifications in order to observe the samples in a more
detailed way.
Zeta potential of loaded nanoparticle formulations was
positive and above 30 mV (p40.05), indicating physically
stable systems prone to interact with the positive ocular
surface. Polydispersity values were low, ranging from
0.106 0.039 to 0.203 0.037, and it also seems to change
independently of daptomycin concentration (p40.05).
Using a rapid and mild method such as ionotropic gelation,
it was possible to obtain daptomycin-loaded nanoparticles
around 200 nm. Similar results were obtained in other studies
with chitosan nanoparticles prepared for encapsulation of
different protein compounds. Pan et al. (2002) obtained
chitosan nanoparticles for intestinal absorption of insulin
with mean particle sizes of 265 nm. Gan & Wang (2007) used
bovine serum albumin (BSA) as a model molecule for
encapsulation into chitosan nanoparticles, which exhibited
mean sizes around 300 nm and a high positive zeta potential.
Considering zeta potential, results of this study were similar to
those obtained by de Campos et al. (2001) and de Salamanca
et al. (2006).
Encapsulation efficiency and release profile
Encapsulation efficiency was very high for all the formula-
tions tested, ranging from 80.82 0.05% to 97.93 0.01%
(Table 2). Generally, an increase in encapsulation efficiency
was observed with increasing daptomycin concentration.
However, statistical analysis revealed that for daptomycin
concentrations above 142.8 mg/ml (daptomycin:chitosan mass
ratio of 0.1:1), an increase in daptomycin concentration does
not significantly affect encapsulation efficiency (p40.05).
Also, no differences were found in the formulations in which
daptomycin was added to chitosan or TPP solution, suggesting
that daptomycin can be added to either solution with no
influence on the final encapsulation (p40.05).
Contradictory results are sometimes observed regarding
the effect of drug concentration on encapsulation efficiency.
Gan & Wang (2007) reported an increase in encapsulation
efficiency of bovine serum albumin (BSA) into chitosan
nanoparticles from 38.7 to 72.5% with increasing protein
concentration. However, many studies have reported oppos-
ite results, such as Xu & Du (2003) who showed that










Daptomycin added to chitosan solution 0.05:1 193.60 44.29 0.185 0.038 þ34.50 3.47 80.82 0.05*
0.1:1 172.50 44.90 0.203 0.037 þ36.36 1.57 93.80 0.02
0.15:1 154.60 32.25 0.163 0.056 þ34.75 5.91 95.20 0.00
0.2:1 147.77 17.86 0.106 0.039 þ38.04 1.34 95.03 0.02
0.3:1 141.63 32.69 0.134 0.036 þ33.99 2.33 97.93 0.01
Daptomycin added to TPP solution 0.05:1 204.20 19.93 0.141 0.049 þ31.72 11.57 82.32 0.02*
0.1:1 177.77 40.37 0.136 0.050 þ33.17 8.70 93.19 0.03
0.15:1 193.37 27.42 0.155 0.008 þ30.26 6.98 96.25 0.03
0.2:1 146.87 30.04 0.144 0.052 þ35.23 8.11 97.09 0.01
0.3:1 144.20 28.99 0.108 0.048 þ34.83 8.75 96.86 0.02
Daptomycin was added to chitosan or TPP solution during nanoparticle preparation. Chitosan concentration: 1.43 mg/mL; TPP concentration:
0.286 mg/mL; daptomycin concentrations: 71.4, 142.8, 214.3, 285.7, and 428.6 mg/ml (corresponding to daptomycin:chitosan mass ratios of 0.05:1,
0.1:1, 0.15:1, 0.2:1, and 0.3:1, respectively). These are final concentrations in nanoparticle suspensions. TPP: sodium tripolyphosphate. Data shown
are the mean standard deviation (n¼ 3).
*Significant at the 0.05 level.
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encapsulation efficiency was significantly affected by BSA
initial concentration, with lower concentrations leading to
higher encapsulation efficiency. Similar results were obtained
by Pan et al. (2002), who reported a slight decrease in
association efficiency with increasing insulin to chitosan
ratio. Different and sometimes inconsistent results could be
due to differences in the experimental conditions and type,
molecular weight, and degree of deacetylation of chitosan,
for example.
Encapsulation efficiency obtained in this study can be
considered very high, with most formulations showing results
over 90%. These results appear to be in agreement with
some other studies with chitosan nanoparticles prepared
by ionotropic gelation. For example, Huang et al. (2009)
obtained insulin-loaded chitosan nanoparticles with average
encapsulation efficiency up to 95.54%. Bayat et al. (2008)
prepared chitosan nanoparticles for oral delivery of insulin
with association efficiency over 84%. de Campos et al. (2001)
obtained an encapsulation efficiency of 73.4% for cyclosporin
A-loaded chitosan nanoparticles, considered particularly
high due to the hydrophobic character of cyclosporin A.
Fernández-Urrusuno et al. (1999) obtained high-encapsula-
tion efficiency values ranging from 87.4 to 96.7% for chitosan
nanoparticles loaded with insulin.
In vitro release profile of daptomycin (Figure 2) revealed a
continuous release of daptomycin from the nanoparticles in
a pH 7.4 medium during a time period of 4 h. Over 90% of
the antibiotic was released during the first 3 h and after 4 h
daptomycin had been completely released from the chitosan
nanoparticles.
Release profiles can vary deeply depending on several
factors, namely the morphology and size of the particulate
system, physicochemical characteristics of the encapsulated
drug, and pH of the release medium (Agnihotri et al., 2004).
Boonsongrit et al. (2006) observed a high burst release of
insulin from chitosan microparticles, with an almost complete
release of the drug within just 10 min in a phosphate buffered
solution (pH¼ 7.4). The authors concluded that the ionic
interaction between insulin and chitosan molecules was too
weak to control the drug release. Similar conclusions were
obtained by Férnandez-Urrusuno et al. (1999), who observed
a complete release of insulin within 2 h.
Concerning daptomycin, it is possible that an initial release




Figure 1. SEM images of unloaded nanoparticles (a) and daptomycin-loaded nanoparticles (b, c, and d). Samples were sputter coated with gold.
Figure 2. In vitro release profile of daptomycin from chitosan
nanoparticles (daptomycin:chitosan mass ratio of 0.3:1). Release assay
was performed in PBS solution, pH¼ 7.4, at 37 C with agitation (n¼ 3).
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the surface of the particles, with 25% of the antibiotic being
released within 30 min of the beginning of the experiment.
During the final part of the experiment, daptomycin release
could be due to instability of the nanoparticulate system
and dissociation of the ionic matrix between chitosan and
daptomycin, leading to a complete release of the antibiotic
within 4 h. Also, at pH 7.4, both chitosan and daptomycin are
negatively charged, reducing ionic interactions between the
molecules. However, more studies should be performed to
further understand the release behavior of daptomycin and
observe if it can be modulated by altering the physicochem-
ical characteristics of the nanoparticles, the molecular weight
of chitosan, and the experimental conditions, for example.
Determination of antimicrobial efficiency
Determination of MIC for free daptomycin and unloaded
and loaded nanoparticles was performed using a broth
microdilution method against eight different microorganisms.
MIC corresponds to the lowest concentration of the agent
tested that inhibits visible bacterial growth (by absence of
turbidity when compared to a control).
MIC values for the different formulations of loaded
nanoparticles were equal or higher than those obtained for
free daptomycin, for every microorganism tested (Table 3).
MIC for free daptomycin (as a daptomycin aqueous solution)
varied between 0.5 and 1 mg/L, and all microorganisms were
susceptible, with MIC below the susceptibility breakpoints
established for staphylococci and enterococci (1 mg/L and
4 mg/L, respectively). MIC for daptomycin-loaded nano-
particles ranged from 1 to 2 mg/L. This decrease in suscep-
tibility when daptomycin was encapsulated into the
nanoparticles could be due to interactions of some free
chitosan with bacterial cells. Chitosan may bind to the
negatively charged bacterial cells and block the access of
daptomycin to its binding sites, leading to a reduction in
antibacterial effect. However, although there was a decrease
in antimicrobial susceptibility of 2-to-4-fold when daptomy-
cin was encapsulated, good results were still obtained for
loaded nanoparticles. Antimicrobial activity of daptomycin
seems to have been preserved when the antibiotic was
encapsulated into chitosan nanoparticles.
Unloaded chitosan nanoparticles were also tested for
their antimicrobial properties (Table 3), since antibacterial
and antifungal activities have been ascribed to chitosan
(Rhoades & Roller, 2000; Fernandes et al., 2008). MIC values
of 16 mg/L were obtained for all the strains tested except
for MSSA and MRSA. For these two strains, at the
highest concentration (16 mg/L), turbidity was observed
when compared to a control, confirming that at this concen-
tration chitosan did not inhibit bacterial growth of MSSA
and MRSA.
Previous studies have suggested that the antibacterial
activity of chitosan may result from its polycationic
structure. Positively charged chitosan may bind to negatively
charged bacterial cells and destabilize the normal function
of the membranes, causing leakage of intracellular compo-
nents or inhibiting the transport of nutrients into the cells
(Du et al., 2009). For example, Qi et al. (2004) obtained MIC
values of 0.125 mg/L for a chitosan nanoparticle suspension
against S. aureus ATCC 25923, compared to 8 mg/L for a
chitosan solution against the same strain. The authors
suggested that chitosan nanoparticles interact with bacterial
cells in a greater degree than chitosan itself due to higher
surface charge density of nanoparticles. Due to their larger
surface area, nanoparticles can be tightly adsorbed onto
the surface of bacterial cells, leading to disruption of the
membrane and death of cells (Qi et al., 2004). These results
are in accordance with those obtained in this study, suggesting
that chitosan nanoparticles can have a high antibacterial
effect.
Stability of nanoparticles in the presence of
lysozyme and mucin
An important aspect of the characterization of nanoparticles is
the evaluation of their stability in the presence of biological
fluids containing proteins, enzymes, or other relevant com-
pounds. In the case of ocular applications, it seems important
to test the stability of nanoparticle formulations in the
presence of two main components of the precorneal fluid:
lysozyme and mucin (de Campos et al., 2004). Thus, the
effect of lysozyme and mucin was tested by observing
the physicochemical characteristics of nanoparticles before
and after incubation with these compounds. Concentrations
of lysozyme and mucin, as well as pH of the solutions, were
chosen considering the physiological characteristics of the
human eye (Calvo et al., 1997b).
Table 3. Minimum inhibitory concentrations (MICs) for daptomycin solution, unloaded chitosan nanoparticles, and daptomycin-loaded chitosan
nanoparticles against eight different Gram-positive bacteria.
MIC (mg/mL)
Daptomycin:Chitosan mass ratio
Microorganism Daptomycin solution Unloaded nanoparticles 0.05:1 0.1:1 0.15:1 0.2:1 0.3:1
Staphylococcus aureus (MSSA) ATCC 25923 0.5 – 2 1 2 2 2
Staphylococcus aureus (MRSA) ATCC 43300 1 – 2 1 2 2 1
Staphylococcus epidermidis ATCC 14990 1 16 2 1 2 2 1
Staphylococcus lugdunensis ATCC 43809 1 16 1 1 1 2 1
Staphylococcus haemolyticus ATCC 29970 0.5 16 1 1 2 2 1
Staphylococcus hominis ATCC 27844 0.5 16 1 1 1 2 2
Staphylococcus warneri ATCC 27836 1 16 2 2 2 2 1
Enterococcus faecalis ATCC 29212 1 16 2 2 1 2 2
MRSA: methicillin-resistant Staphylococcus aureus; MSSA: methicillin-susceptible Staphylococcus aureus.
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Results present in Table 4 show an apparent reduction in
nanoparticle size upon incubation with lysozyme; however,
this only occurred for nanoparticles with daptomycin:chitosan
mass ratios of 0.05:1 and 0.1:1. For the other formulations,
particle size increased. However, statistical analysis revealed
no significant differences in the size of nanoparticles before
and after incubation with lysozyme (p40.05). Concerning
zeta potential, no significant differences were found before
and after incubation with this enzyme (p40.05). Since
lysozyme is a cationic protein, interactions with the positively
charged nanoparticles does not significantly affect their zeta
potential due to electrostatic repulsion.
Incubation of loaded nanoparticles with mucin did no
significantly affect their size (p40.05). Nonetheless, results
of zeta potential suggest an interaction between mucin and
chitosan nanoparticles. Before incubation with mucin,
nanoparticles showed zeta potential values above þ23 mV.
However, after incubation, zeta potential decreased signifi-
cantly (p50.05), with all formulations showing negative
values. This reduction could be attributed to ionic interactions
and consequent bonding of negatively charged mucin onto the
surface of positively charged nanoparticles. This ionic
interaction between mucin and chitosan nanoparticles is
favorable to prolong the contact time between nanoparticles
and the mucus layer of the eye surface, thus contributing
to the absorption of the drug and reduction of the frequency
of administration (Dudhani & Kosaraju, 2010).
Thus, this stability study suggests that lysozyme does not
significantly affect the integrity of chitosan nanoparticles
within 2 h of incubation. However, the presence of mucin
significantly alters the surface charge of the nanoparticles,
changing from positive to negative values, which is important
for interaction and association of the nanoparticles to the
mucosal tissues of the eye.
Conclusion
This is the first time, to our knowledge, that mucoadhesive
chitosan nanoparticles were prepared for encapsulation of
daptomycin, as an alternative therapy for the treatment
of ocular infections caused by Gram-positive bacteria,
particularly in endophthalmitis cases. The obtained nanopar-
ticles have appropriate characteristics for topical ocular
administration and antimicrobial activity of daptomycin was
preserved after encapsulation. Loaded nanoparticles were
able to interact with mucin, a component of ocular fluids
important for the desirable mucoadhesiveness of the delivery
system. This nanoparticulate system could arise as a possible
way to deliver the antibiotic directly to the site of infection
and enhance its residence time in the eye.
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de la Fuente M, Ravinã M, Paolicelli P, et al. (2010). Chitosan-based
nanostructures: a delivery platform for ocular therapeutics. Adv Drug
Deliv Rev 62:100–17.
de Salamanca AE, Diebold Y, Calonge M, et al. (2006). Chitosan
nanoparticles as a potential drug delivery system for the ocular
surface: toxicity, uptake mechanism and in vivo tolerance. Inves
Ophthalmo Vis Sci 47:1416–25.
Diebold Y, Calonge M. (2010). Applications of nanoparticles in
ophthalmology. Prog Retin Eye Res 29:596–609.
Ding S. (1998). Recent developments in ophthalmic drug delivery.
Pharm Sci Technolo Today 1:328–35.
Du W, Niu S, Xu Y, et al. (2009). Antibacterial activity of chitosan
tripolyphosphate nanoparticles loaded with various metal ions.
Carbohydr Polym 75:385–9.
Dudhani AR, Kosaraju SL. (2010). Bioadhesive chitosan nanoparticles:
preparation and characterization. Carbohydr Polym 81:243–51.
Enoch DA, Bygott JM, Daly M, Karas A. (2007). Daptomycin. J Infect
55:205–13.
Fernandes JC, Tavaria FK, Soares JC, et al. (2008). Antimicrobial effects
of chitosans and chitooligosaccharides, upon Staphylococcus aureus
and Escherichia coli, in food model systems. Food Microbiol 25:
922–8.
Fernández-Urrusuno R, Calvo P, Remuñán-López C, et al. (1999).
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